Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adagio Medical Holdings ( (ADGM) ) just unveiled an update.
On April 26, 2026, Adagio Medical reported positive six‑month pivotal results from its FULCRUM‑VT IDE trial of the vCLAS ventricular ablation system in patients with ischemic and non‑ischemic structural heart disease. The study met safety and effectiveness endpoints, showing 98% acute non‑inducibility of targeted ventricular tachycardias, 84% freedom from implantable cardioverter defibrillator shocks, 59% freedom from VT recurrence, and a 2.4% major adverse event rate.
The results demonstrated equivalent performance in ischemic and non‑ischemic cardiomyopathy, significant reductions in ICD shocks and VT‑related hospital readmissions, and broad de‑escalation of amiodarone use. These pivotal data, presented at the Heart Rhythm Society 2026 conference, position ULTA and the vCLAS system as a potential new benchmark for endocardial VT ablation and will support Adagio’s planned FDA premarket approval application, with implications for both clinical practice and the large VT patient population.
The most recent analyst rating on (ADGM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, sustained losses, and ongoing cash burn with elevated leverage). Technicals are a key offset with price trending above major moving averages and positive momentum, while valuation remains constrained by losses (negative P/E). A positive FDA IDE trial expansion supports the outlook but does not yet change near-term financial risk.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in catheter-based ablation technologies for the treatment of cardiac arrhythmias, built around its proprietary Ultra-Low Temperature Ablation (ULTA) platform. The company is currently focused on ventricular arrhythmias with its purpose-built vCLAS cryoablation system, which is CE marked in Europe and under evaluation in the FULCRUM-VT U.S. pivotal IDE trial for potential FDA approval.
Average Trading Volume: 95,081
Technical Sentiment Signal: Hold
Current Market Cap: $33.54M
For detailed information about ADGM stock, go to TipRanks’ Stock Analysis page.